|
Market Closed -
Nasdaq
00:00:00 26/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 2.170 USD | +6.90% |
|
+6.90% | +58.39% |
| 08-13 | Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says | MT |
| 08-13 | Allogene Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 750M | - | - | - | - | - |
| 71.35B | |||||
| 64.17B | |||||
| 28.65B | - | ||||
| 27.06B | - | ||||
| 27.33B |
Select your edition
All financial news and data tailored to specific country editions
